Literature DB >> 8057828

Simple method of purification of Escherichia coli heat-labile enterotoxin and cholera toxin using immobilized galactose.

Y Uesaka1, Y Otsuka, Z Lin, S Yamasaki, J Yamaoka, H Kurazono, Y Takeda.   

Abstract

A simple method for purification of heat-labile enterotoxin produced by enterotoxigenic Escherichia coli and for purification of cholera toxin using immobilized D-galactose column is described. A single run of column chromatography yielded homogeneous toxin as demonstrated by sodium dodecyl sulfate polyacrylamide slab gel electrophoresis.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8057828     DOI： 10.1006/mpat.1994.1007

Source DB:  PubMed          Journal:  Microb Pathog        ISSN： 0882-4010            Impact factor:   3.738


  23 in total

1.  Cholera holotoxin assembly requires a hydrophobic domain at the A-B5 interface: mutational analysis and development of an in vitro assembly system.

Authors:  Juliette K Tinker; Jarrod L Erbe; Wim G J Hol; Randall K Holmes
Journal:  Infect Immun       Date:  2003-07       Impact factor: 3.441

2.  Enterotoxigenic Escherichia coli modulates host intestinal cell membrane asymmetry and metabolic activity.

Authors:  Amber M Johnson; Radhey S Kaushik; Nicholas J Rotella; Philip R Hardwidge
Journal:  Infect Immun       Date:  2008-10-20       Impact factor: 3.441

3.  Transcytosis-blocking abs elicited by an oligomeric immunogen based on the membrane proximal region of HIV-1 gp41 target non-neutralizing epitopes.

Authors:  Nobuyuki Matoba; Tagan A Griffin; Michele Mittman; Jeffrey D Doran; Annette Alfsen; David C Montefiori; Carl V Hanson; Morgane Bomsel; Tsafrir S Mor
Journal:  Curr HIV Res       Date:  2008-05       Impact factor: 1.581

4.  An orally applicable Shiga toxin neutralizer functions in the intestine to inhibit the intracellular transport of the toxin.

Authors:  Miho Watanabe-Takahashi; Toshio Sato; Taeko Dohi; Noriko Noguchi; Fumi Kano; Masayuki Murata; Takashi Hamabata; Yasuhiro Natori; Kiyotaka Nishikawa
Journal:  Infect Immun       Date:  2009-10-26       Impact factor: 3.441

5.  Mutants of the Escherichia coli heat-labile enterotoxin with reduced ADP-ribosylation activity or no activity retain the immunogenic properties of the native holotoxin.

Authors:  L de Haan; W R Verweij; I K Feil; T H Lijnema; W G Hol; E Agsteribbe; J Wilschut
Journal:  Infect Immun       Date:  1996-12       Impact factor: 3.441

6.  Enterotoxin-based mucosal adjuvants alter antigen trafficking and induce inflammatory responses in the nasal tract.

Authors:  Frederik W van Ginkel; Raymond J Jackson; Naoto Yoshino; Yukari Hagiwara; Daniel J Metzger; Terry D Connell; Hong L Vu; Michael Martin; Kohtaro Fujihashi; Jerry R McGhee
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

7.  Novel Cholera Toxin Variant and ToxT Regulon in Environmental Vibrio mimicus Isolates: Potential Resources for the Evolution of Vibrio cholerae Hybrid Strains.

Authors:  Sucharit Basu Neogi; Nityananda Chowdhury; Sharda Prasad Awasthi; Masahiro Asakura; Kentaro Okuno; Zahid Hayat Mahmud; Mohammad Sirajul Islam; Atsushi Hinenoya; Gopinath Balakrish Nair; Shinji Yamasaki
Journal:  Appl Environ Microbiol       Date:  2019-01-23       Impact factor: 4.792

8.  A second generation of double mutant cholera toxin adjuvants: enhanced immunity without intracellular trafficking.

Authors:  Yukari Hagiwara; Yuki I Kawamura; Kosuke Kataoka; Bibi Rahima; Raymond J Jackson; Katsuhiro Komase; Taeko Dohi; Prosper N Boyaka; Yoshifumi Takeda; Hiroshi Kiyono; Jerry R McGhee; Kohtaro Fujihashi
Journal:  J Immunol       Date:  2006-09-01       Impact factor: 5.422

9.  Molecular characterizations of cytolethal distending toxin produced by Providencia alcalifaciens strains isolated from patients with diarrhea.

Authors:  Ayaka Shima; Atsushi Hinenoya; Masahiro Asakura; Norihiko Sugimoto; Teizo Tsukamoto; Hideaki Ito; Akira Nagita; Shah M Faruque; Shinji Yamasaki
Journal:  Infect Immun       Date:  2012-01-17       Impact factor: 3.441

10.  A nontoxic cholera enterotoxin (CT) analog is chimeric with regard to both epitypes of CT-B subunits, CT-B-1 and CT-B-2.

Authors:  M Boesman-Finkelstein; J W Peterson; L S Thai; R A Finkelstein
Journal:  Infect Immun       Date:  1996-01       Impact factor: 3.441
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.